Skip to main content

Fractures, Bone

1
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
Denosumab 70 mg/mLPhase 3
TZD onlyN/A
Bioretec
BioretecFinland - Tampere
1 program
Biodegradable Intramedullary NailingN/A1 trial
Active Trials
NCT04385745Completed15Est. Jan 2023
Zimmer Biomet
Zimmer BiometFL - Jacksonville
1 program
Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.N/A1 trial
Active Trials
NCT04002518Active Not Recruiting51Est. Dec 2026
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Blood draws to assess RNA expression levelsN/A1 trial
Active Trials
NCT06872775Enrolling By Invitation110Est. Aug 2028
GSK
GSKLONDON, United Kingdom
1 program
TZD onlyN/A1 trial
Active Trials
NCT01055223Completed98,483Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Human BioSciencesBlood draws to assess RNA expression levels
Zimmer BiometBiomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.
BioretecBiodegradable Intramedullary Nailing
GSKTZD only

Clinical Trials (4)

Total enrollment: 98,659 patients across 4 trials

NCT06872775Human BioSciencesBlood draws to assess RNA expression levels

855303-RNA Biomarker Validation

Start: Aug 2025Est. completion: Aug 2028110 patients
N/AEnrolling By Invitation
NCT04002518Zimmer BiometBiomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.

MDR - Biomet Cannulated Screws

Start: Aug 2019Est. completion: Dec 202651 patients
N/AActive Not Recruiting
NCT04385745BioretecBiodegradable Intramedullary Nailing

Treatment of Children's Forearm Shaft Fractures With Biodegradable Intramedullary Nailing, Compared With Elastic Stable Intramedullary Nailing

Start: Jan 2019Est. completion: Jan 202315 patients
N/ACompleted

Fracture Risk With Thiazolidinediones

Start: May 2009Est. completion: Mar 201098,483 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.